PAREXEL wins 2010 Scrip Award for 'Clinical Research Team of the Year'

PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has won the 2010 Scrip Award for "Clinical Research Team of the Year."  The award was presented to PAREXEL at the sixth annual Scrip Awards ceremony, hosted by Scrip Intelligence, a leading news, data, and information service for the global pharmaceutical industry, on November 4, 2010 in London, England.  The annual Scrip Awards, which are independently judged by a panel of senior industry experts, honor contributions to the advancement of science and improvement of healthcare worldwide.  The panel of judges chose PAREXEL as the winner of the Clinical Research Team of the Year Award over the research teams of other clinical research organization (CRO) nominees, as well as in-house research teams from pharmaceutical companies.

According to Philip Jarvis, Publisher of Scrip Intelligence, "The Scrip Award for Clinical Research Team of the Year honors the achievement of the team that has made the most difference to a pharmaceutical or biotechnology company's research program.  The Scrip Award recognizes the PAREXEL team's outstanding work in performing a great task, given the drug, target population, and number of centers and countries involved—ultimately assisting the sponsor in securing a patent extension and extending access of an important proprietary product. The judges were particularly impressed with the clinical research team's ability to rapidly complete study start-up and implement the required timelines. The PAREXEL team demonstrated excellence not only in managing a complex global trial, but also in driving greater efficiencies through best practices and innovation as part of a wider strategic partnership."

"PAREXEL is honored to receive the Clinical Research Team of the Year Award, and have our achievements recognized by the judges of the Scrip Awards," said Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL International.  "This recognition reflects our continued commitment to clients to deliver high levels of quality and best-practice outsourcing approaches focused on significant value creation.  We are pleased that the judges recognized this team's performance in the context of a strategic partnership that leveraged a new operational model to improve effectiveness and accelerate development."

PAREXEL continues to be a premier, trusted partner to clients who rely on the Company for expertise and flexibility as well as the efficiencies of a worldwide infrastructure, to help them more quickly achieve their goals. PAREXEL complements client organizations with strategic insight, in-depth scientific knowledge, tactical expertise, and a wealth of experience throughout the product development process, including worldwide regulatory expertise, Phase I-IV clinical research services, eClinical technologies that accelerate development, and medical communications services, as well as reimbursement and market access services. PAREXEL is focused on providing tailored solutions that match a client's specific needs by applying the right blend of resources and capabilities, as well as the right guidance and high level of quality, needed to help clients bring safe and effective treatments to patients sooner.